Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Offers synthesis of emerging HF biomarkers; leaves open their clinical adoption pending prospective validation.
A growing array of biological pathways underpins the syndrome we recognize as heart failure. These include both deleterious pathways promoting its development and progression, as well as compensatory cardioprotective pathways. Components of these pathways can be utilized as biomarkers of this condition to aid diagnosis, prognostication and potentially guide management. As our understanding of the pathophysiology of heart failure deepens further candidate biomarkers are being identified. We provide an overview of the more recently emerging biomarkers displaying potential promise for future clinical use.
No takes yet. Share an insight, caveat, or question.
Dalzell et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: